Alivus Life Sciences reports strong Q2 growth, anticipates second half rebound

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced revenue of INR588 crores for the second quarter of FY26, marking a 16% year-on-year growth. This was largely attributed to 39.7% growth in its non-GPL business, bolstered by successful new product launches, despite moderation in overall growth due to a decline in the GPL segment. Gross profit for the quarter stood at INR339 crores, up 20.4% year-on-year, with gross margins at 57.7%. EBITDA reached INR194 crores, a 35.7% year-on-year increase, resulting in an EBITDA margin of 33%. PAT for the quarter was INR130 crores with PAT margins at 22.1%.

For the first half of FY26, revenue from operations was INR1,190 crores, an 8.6% year-on-year increase. The company expects the GPL business to regain momentum in the second half of FY26 and anticipates a turnaround in CDMO performance, driven by new projects and ramp-ups across existing projects. The pipeline remains strong with 586 DMF and CEP filings globally.

Alivus Life Sciences maintains a net debt-free status, generating INR148 crores in cash flow from operations in H1 FY26, with cash and cash equivalents, including short-term investments, totaling INR653 crores as of September 30, 2025. The company reaffirmed its guidance of high single-digit revenue growth for FY26, with strong performance expected in the second half due to external sales, GPL business recovery, and CDMO project ramp-up.